Recent Analysts’ Ratings Changes for Edwards Lifesciences (EW)

Edwards Lifesciences (NYSE: EW) has recently received a number of price target changes and ratings updates:

• 7/13/2026 – Edwards Lifesciences had its price target raised by Royal Bank Of Canada from $100.00 to $110.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – Edwards Lifesciences had its price target raised by Citigroup Inc. from $101.00 to $110.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Edwards Lifesciences had its “outperform” rating reaffirmed by Evercore Inc. They now have a $100.00 price target on the stock.
• 7/4/2026 – Edwards Lifesciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/30/2026 – Edwards Lifesciences had its price target raised by BTIG Research from $100.00 to $110.00. They now have a “buy” rating on the stock.
• 6/16/2026 – Edwards Lifesciences had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $100.00 price target on the stock.
• 6/2/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by TD Cowen. They now have a $104.00 price target on the stock, up from $97.00.

Insider Buying and Selling

In other news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $91.70, for a total value of $56,762.30. Following the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,671,117.80. The trade was a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 45,577 shares of company stock valued at $3,855,527 over the last 90 days. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.